Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation

Molecules

Volumn 17, Issue 6, 2012, Pages 6854-6868

  Mu, Xianmin ^a,b   Shi, Wei ^c   Sun, Lixin ^a   Li, Han ^a   Jiang, Zhenzhou ^a   Zhang, Luyong ^a,d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Akt mTOR; Angiogenesis; Cancer; KDR Flk 1; Pristimerin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PRISTIMERIN; TRITERPENE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL MOTION; CHEMISTRY; CHICK EMBRYO; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; THORACIC AORTA; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA, THORACIC; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863000261     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17066869     Document Type: Article

References (35)

1. Weis, S. M.; Cheresh, D. A. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat. Med. 2011, 17, 1359-1370.
2. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
3. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358, 2039-2049. (Pubitemid 351656458)
4. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 2006, 12, 5018-5022. (Pubitemid 44453326)
5. Pyun, B. J.; Choi, S.; Lee, Y.; Kim, T. W.; Min, J. K.; Kim, Y.; Kim, B. D.; Kim, J. H.; Kim, T. Y.; Kim, Y. M.; et al. Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res. 2008, 68, 227-235. (Pubitemid 351380124)
6. Falcon, B. L.; Barr, S.; Gokhale, P. C.; Chou, J.; Fogarty, J.; Depeille, P.; Miglarese, M.; Epstein, D. M.; McDonald, D. M. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011, 71, 1573-1583.
7. Burstein, H. J.; Schwartz, R. S. Molecular origins of cancer. N. Engl. J. Med. 2008, 358, 527. (Pubitemid 351185811)
8. Costa, P. M.; Ferreira, P. M.; Bolzani Vda, S.; Furlan, M.; de Freitas Formenton Macedo Dos Santos, V. A.; Corsino, J.; de Moraes, M. O.; Costa-Lotufo, L. V.; Montenegro, R. C.; Pessoa, C. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol. In Vitro 2008, 22, 854-863.
9. Tiedemann, R. E.; Schmidt, J.; Keats, J. J.; Shi, C. X.; Zhu, Y. X.; Palmer, S. E.; Mao, X.; Schimmer, A. D.; Stewart, A. K. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 2009, 113, 4027-4037.
10. Byun, J. Y.; Kim, M. J.; Eum, D. Y.; Yoon, C. H.; Seo, W. D.; Park, K. H.; Hyun, J. W.; Lee, Y. S.; Lee, J. S.; Yoon, M. Y.; et al. Reactive oxygen species-dependent activation of Bax and poly (ADPribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol. Pharmacol. 2009, 76, 734-744.
11. Yang, H.; Landis-Piwowar, K. R.; Lu, D.; Yuan, P.; Li, L.; Reddy, G. P.; Yuan, X.; Dou, Q. P. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J. Cell Biochem. 2008, 103, 234-244.
12. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120, 303-313. (Pubitemid 40222426)
13. Wu, C. C.; Chan, M. L.; Chen, W. Y.; Tsai, C. Y.; Chang, F. R.; Wu, Y. C. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol. Cancer Ther. 2005, 4, 1277-1285.
14. Chen, Y.; Lu, N.; Ling, Y.; Wang, L.; You, Q.; Li, Z.; Guo, Q. LYG-202, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo. J. Pharmacol. Sci. 2010, 112, 37-45.
15. Taraboletti, G.; Giavazzi, R. Modelling approaches for angiogenesis. Eur. J. Cancer 2004, 40, 881-889. (Pubitemid 38519766)
16. Sheng, H.; Sun, H. Synthesis, biology and clinical significance of pentacyclic triterpenes: A multi-target approach to prevention and treatment of metabolic and vascular diseases. Nat. Prod. Rep. 2011, 28, 543-593.
17. Salminen, A.; Lehtonen, M.; Suuronen, T.; Kaarniranta, K.; Huuskonen, J. Terpenoids: Natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol. Life Sci. 2008, 65, 2979-2999.
18. Pang, X.; Yi, Z.; Zhang, J.; Lu, B.; Sung, B.; Qu, W.; Aggarwal, B. B.; Liu, M. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010, 70, 1951-1959.
19. Yadav, V. R.; Prasad, S.; Sung, B.; Kannappan, R.; Aggarwal, B. B. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2010, 2, 2428-2466.
20. Napoleone Ferrara, R. S. K. Angiogenesis as a therapeutic target. Nature 2005, 438, 967-974.
21. Holmes, K.; Roberts, O. L.; Thomas, A. M.; Cross, M. J. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal. 2007, 19, 2003-2012. (Pubitemid 47354167)
22. Huang, D.; Ding, Y.; Luo, W. M.; Bender, S.; Qian, C. N.; Kort, E.; Zhang, Z. F.; VandenBeldt, K.; Duesbery, N. S.; Resau, J. H.; Teh, B. T. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 2008, 68, 81-88. (Pubitemid 351380108)
23. Hers, I.; Vincent, E. E.; Tavare, J. M. Akt signalling in health and disease. Cell Signal. 2011, 23, 1515-1527.
24. Pang, X.; Zhang, L.; Wu, Y.; Lin, L.; Li, J.; Qu, W.; Safe, S.; Liu, M. Methyl 2-cyano-3, 11-dioxo-18-olean-1, 12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor. J. Pharmacol. Exp. Ther. 2010, 335, 172-179.
25. Lee, D. F.; Kuo, H. P.; Chen, C. T.; Hsu, J. M.; Chou, C. K.; Wei, Y.; Sun, H. L.; Li, L. Y.; Ping, B.; Huang, W. C.; et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130, 440-455. (Pubitemid 47198298)
26. LoPiccolo, J.; Blumenthal, G. M.; Bernstein, W. B.; Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11, 32-50.
27. Berven, L. A.; Willard, F. S.; Crouch, M. F. Role of the p70 (S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp. Cell Res. 2004, 296, 183-195. (Pubitemid 38624640)
28. Lu, Z.; Jin, Y.; Chen, C.; Li, J.; Cao, Q.; Pan, J. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol. Cancer 2010, 9, 112.
29. Garcia-Maceira, P.; Mateo, J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009, 28, 313-324.
30. Weng, Q.; Zhang, J.; Cao, J.; Xia, Q.; Wang, D.; Hu, Y.; Sheng, R.; Wu, H.; Zhu, D.; Zhu, H.; He, Q.; Yang, B. Q39, a quinoxaline 1, 4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1alpha expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells. Invest. New Drugs 2011, 29, 1177-1187.
31. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W. G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D. J.; et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69, 6232-6240.
32. Pang, X.; Yi, T.; Yi, Z.; Cho, S. G.; Qu, W.; Pinkaew, D.; Fujise, K.; Liu, M. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signalregulated kinase signaling pathways. Cancer Res. 2009, 69, 518-525.
33. Inao, T.; Harashima, N.; Monma, H.; Okano, S.; Itakura, M.; Tanaka, T.; Tajima, Y.; Harada, M. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly (I:C), on human breast cancer. Breast Cancer Res. Treat. 2011, doi:10.1007/s10549-011-1930-3.
34. Abdel-Malak, N. A.; Mofarrahi, M.; Mayaki, D.; Khachigian, L. M.; Hussain, S. N. Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 209-216.
35. Pisanti, S.; Picardi, P.; Prota, L.; Proto, M. C.; Laezza, C.; McGuire, P. G.; Morbidelli, L.; Gazzerro, P.; Ziche, M.; Das, A.; Bifulco, M. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 2011, 117, 5541-5550.